Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC. Declan ...
Himalayas-1 randomizes 1:1 to rinzimetostat 400 mg daily plus darolutamide vs physician’s choice ARPI or docetaxel in mCRPC progressing after abiraterone. Radiographic PFS is the primary end point, ...
A recap of the FDA submissions and regulatory decisions in urology from June 2026. Welcome to Urology Times’® monthly FDA update! June 2026 brought a wave of regulatory developments across the urology ...
The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC. According to Barata, ...
A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology. Urologists will soon gather in Washington, DC, for the 2026 Annual Meeting of the American ...
The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...
FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...
A recap of the FDA approvals and clearances across urology from January through March. The first quarter of 2026 brought a wave of regulatory activity across the urology landscape, with 8 distinct FDA ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
The ANDROMEDA trial compares alpha-emitting 225Ac-PSMA-617 and beta-emitting 177Lu-PSMA-617 with SBRT for recurrent oligometastatic prostate cancer. The trial builds on the LUNAR trial, which showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results